Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 593

1.

Cost-effectiveness of screening BRCA1/2 mutation carriers with breast magnetic resonance imaging.

Plevritis SK, Kurian AW, Sigal BM, Daniel BL, Ikeda DM, Stockdale FE, Garber AM.

JAMA. 2006 May 24;295(20):2374-84.

PMID:
16720823
2.

Cost-effectiveness of alternating magnetic resonance imaging and digital mammography screening in BRCA1 and BRCA2 gene mutation carriers.

Cott Chubiz JE, Lee JM, Gilmore ME, Kong CY, Lowry KP, Halpern EF, McMahon PM, Ryan PD, Gazelle GS.

Cancer. 2013 Mar 15;119(6):1266-76. doi: 10.1002/cncr.27864. Epub 2012 Nov 26.

3.

Cost-effectiveness of MRI for breast cancer screening in BRCA1/2 mutation carriers.

Pataky R, Armstrong L, Chia S, Coldman AJ, Kim-Sing C, McGillivray B, Scott J, Wilson CM, Peacock S.

BMC Cancer. 2013 Jul 10;13:339. doi: 10.1186/1471-2407-13-339.

4.

Cost-effectiveness of breast MR imaging and screen-film mammography for screening BRCA1 gene mutation carriers.

Lee JM, McMahon PM, Kong CY, Kopans DB, Ryan PD, Ozanne EM, Halpern EF, Gazelle GS.

Radiology. 2010 Mar;254(3):793-800. doi: 10.1148/radiol.09091086.

5.

Cost-effectiveness of screening with contrast enhanced magnetic resonance imaging vs X-ray mammography of women at a high familial risk of breast cancer.

Griebsch I, Brown J, Boggis C, Dixon A, Dixon M, Easton D, Eeles R, Evans DG, Gilbert FJ, Hawnaur J, Kessar P, Lakhani SR, Moss SM, Nerurkar A, Padhani AR, Pointon LJ, Potterton J, Thompson D, Turnbull LW, Walker LG, Warren R, Leach MO; UK Magnetic Resonance Imaging in Breast Screening (MARIBS) Study Group.

Br J Cancer. 2006 Oct 9;95(7):801-10.

6.

Should women with a BRCA1/2 mutation aged 60 and older be offered intensified breast cancer screening? - A cost-effectiveness analysis.

Phi XA, Greuter MJW, Obdeijn IM, Oosterwijk JC, Feenstra TL, Houssami N, de Bock GH.

Breast. 2019 Jun;45:82-88. doi: 10.1016/j.breast.2019.03.004. Epub 2019 Mar 12.

PMID:
30904701
7.

Cost-effectiveness of screening women with familial risk for breast cancer with magnetic resonance imaging.

Saadatmand S, Tilanus-Linthorst MM, Rutgers EJ, Hoogerbrugge N, Oosterwijk JC, Tollenaar RA, Hooning M, Loo CE, Obdeijn IM, Heijnsdijk EA, de Koning HJ.

J Natl Cancer Inst. 2013 Sep 4;105(17):1314-21. doi: 10.1093/jnci/djt203. Epub 2013 Aug 12.

PMID:
23940285
8.

Annual screening strategies in BRCA1 and BRCA2 gene mutation carriers: a comparative effectiveness analysis.

Lowry KP, Lee JM, Kong CY, McMahon PM, Gilmore ME, Cott Chubiz JE, Pisano ED, Gatsonis C, Ryan PD, Ozanne EM, Gazelle GS.

Cancer. 2012 Apr 15;118(8):2021-30. doi: 10.1002/cncr.26424. Epub 2011 Sep 20. Erratum in: Cancer. 2012 Nov 1;118(21):5448.

9.

Comparative effectiveness of screening and prevention strategies among BRCA1/2-affected mutation carriers.

Grann VR, Patel PR, Jacobson JS, Warner E, Heitjan DF, Ashby-Thompson M, Hershman DL, Neugut AI.

Breast Cancer Res Treat. 2011 Feb;125(3):837-47. doi: 10.1007/s10549-010-1043-4. Epub 2010 Jul 20.

10.

Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination.

Warner E, Plewes DB, Hill KA, Causer PA, Zubovits JT, Jong RA, Cutrara MR, DeBoer G, Yaffe MJ, Messner SJ, Meschino WS, Piron CA, Narod SA.

JAMA. 2004 Sep 15;292(11):1317-25.

PMID:
15367553
12.

Which screening strategy should be offered to women with BRCA1 or BRCA2 mutations? A simulation of comparative cost-effectiveness.

de Bock GH, Vermeulen KM, Jansen L, Oosterwijk JC, Siesling S, Dorrius MD, Feenstra T, Houssami N, Greuter MJ.

Br J Cancer. 2013 Apr 30;108(8):1579-86. doi: 10.1038/bjc.2013.149. Epub 2013 Apr 11.

13.

Cost-effectiveness of preventive strategies for women with a BRCA1 or a BRCA2 mutation.

Anderson K, Jacobson JS, Heitjan DF, Zivin JG, Hershman D, Neugut AI, Grann VR.

Ann Intern Med. 2006 Mar 21;144(6):397-406.

PMID:
16549852
14.

Survival analysis of cancer risk reduction strategies for BRCA1/2 mutation carriers.

Kurian AW, Sigal BM, Plevritis SK.

J Clin Oncol. 2010 Jan 10;28(2):222-31. doi: 10.1200/JCO.2009.22.7991. Epub 2009 Dec 7.

15.

Cost-effectiveness of MRI compared to mammography for breast cancer screening in a high risk population.

Moore SG, Shenoy PJ, Fanucchi L, Tumeh JW, Flowers CR.

BMC Health Serv Res. 2009 Jan 13;9:9. doi: 10.1186/1472-6963-9-9.

16.

Contribution of mammography to MRI screening in BRCA mutation carriers by BRCA status and age: individual patient data meta-analysis.

Phi XA, Saadatmand S, De Bock GH, Warner E, Sardanelli F, Leach MO, Riedl CC, Trop I, Hooning MJ, Mandel R, Santoro F, Kwan-Lim G, Helbich TH, Tilanus-Linthorst MM, van den Heuvel ER, Houssami N.

Br J Cancer. 2016 Mar 15;114(6):631-7. doi: 10.1038/bjc.2016.32. Epub 2016 Feb 23.

17.

Differences in natural history between breast cancers in BRCA1 and BRCA2 mutation carriers and effects of MRI screening-MRISC, MARIBS, and Canadian studies combined.

Heijnsdijk EA, Warner E, Gilbert FJ, Tilanus-Linthorst MM, Evans G, Causer PA, Eeles RA, Kaas R, Draisma G, Ramsay EA, Warren RM, Hill KA, Hoogerbrugge N, Wasser MN, Bergers E, Oosterwijk JC, Hooning MJ, Rutgers EJ, Klijn JG, Plewes DB, Leach MO, de Koning HJ.

Cancer Epidemiol Biomarkers Prev. 2012 Sep;21(9):1458-68. doi: 10.1158/1055-9965.EPI-11-1196. Epub 2012 Jun 28.

18.

Relevance and efficacy of breast cancer screening in BRCA1 and BRCA2 mutation carriers above 60 years: a national cohort study.

Saadatmand S, Vos JR, Hooning MJ, Oosterwijk JC, Koppert LB, de Bock GH, Ausems MG, van Asperen CJ, Aalfs CM, Gómez Garcia EB, Meijers-Heijboer H, Hoogerbrugge N, Piek M, Seynaeve C, Verhoef C, Rookus M, Tilanus-Linthorst MM; Hereditary Breast and Ovarian Cancer Research Group Netherlands (HEBON).

Int J Cancer. 2014 Dec 15;135(12):2940-9. doi: 10.1002/ijc.28941. Epub 2014 May 20.

19.

Comparison of costs and benefits of breast cancer screening with mammography, ultrasonography, and MRI.

Feig S.

Obstet Gynecol Clin North Am. 2011 Mar;38(1):179-96, ix. doi: 10.1016/j.ogc.2011.02.009.

PMID:
21419333
20.

Breast cancer screening in BRCA1 mutation carriers: effectiveness of MR imaging--Markov Monte Carlo decision analysis.

Lee JM, Kopans DB, McMahon PM, Halpern EF, Ryan PD, Weinstein MC, Gazelle GS.

Radiology. 2008 Mar;246(3):763-71. doi: 10.1148/radiol.2463070224.

PMID:
18309013

Supplemental Content

Support Center